The global women’s health market size was exhibited at USD 44.75 billion in 2023 and is projected to hit around USD 79.39 billion by 2033, growing at a CAGR of 5.9% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 47.39 Billion |
| Market Size by 2033 | USD 79.39 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 5.9% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Application, Age, Drug, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Key Companies Profiled | AbbVie, Inc.; Bayer AG; Merck & Co., Inc.; Pfizer, Inc; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; Amgen, Inc; Apothecus Pharmaceutical Corp.; Blairex Laboratories, Inc.; and Ferring B.V. |
Market growth can be attributed to the increase in the geriatric population of women and the introduction of new advanced therapeutic products for women’s health, such as Relugoliz and Orilissa. Furthermore, favorable policies initiated by governments to improve women’s health and raise awareness are likely to drive market growth during the forecast period. The market exhibited slower growth during the pandemic.
Access to gynecological testing and contraception has fallen, raising the rate of unsafe abortions and unwanted pregnancies, especially in developing nations. Moreover, according to BMC, in low- and middle-income countries, there has been around a 10% decline in the use of long- and short-acting reversible contraceptives and about a 10% decline in basic services related to pregnancy care. These factors led to a reduction in market growth during the pandemic. Women are more exposed to various diseases such as osteoporosis, endometriosis, osteoarthritis, and menstrual health disorders.
Approximately 73% of postmenopausal women experience fatigue, hot flashes, and sleep disturbances, which increase dependency on medications, decreasing the quality of life. With aging population and the rising prevalence of obesity, osteoporosis is expected to grow. Some of the major factors leading to hormonal imbalance in women are changes in dietary habits, stress, and alcohol consumption, which are expected to cause fertility issues in women. Ovulation problems, PCOS, and endometriosis are some of the major causes of infertility. In August 2023, the University at Buffalo published new research on the relationship between pain in endometriosis and endometrial lesions. The research is expected to lead to new therapies for this painful, chronic, and inadequately understood condition that affects around 5-10% of women globally and costs an estimated USD 69 billion in surgical and medical expenses.
These factors are anticipated to fuel market growth. According to the Society of Family Planning's #WeCount Report, in the U.S., from July 2022 to June 2023, the average monthly number of abortions was 82,298. Owing to the high unmet need for publicly funded contraceptive services and products, federal & state governments are actively working toward improving family planning services and improving access to modern contraceptives. Market players are adopting various market strategies, such as collaboration and awareness and marketing campaigns, to increase their market penetration in the country. For instance, in October 2022, Abbott conducted a survey in partnership with Ipsos to raise awareness and support women during the menopause phase. Moreover, Abbott is planning to launch, The Next Chapter campaign, to raise awareness among women with menopause
According to the United Nations Population Fund's (UNFPA) article published in September 2023, philanthropies and governments invest in family planning supplies. The Bill & Melinda Gates Foundation invested up to USD 100 million in the UNFPA Supplies Partnership. The Government of Germany invested USD 50.5 million to support the UNFPA Supplies Partnership. Furthermore, agencies such as USAID conduct family planning & reproductive health programs in more than 30 countries, including South Africa & other African countries, where there is a high unmet need for contraception. However, there are various complications and negative effects of the continuous use of contraceptives, which lead to an increase in the adoption of traditional contraceptive methods.
The contraceptives segment held the highest market share of more than 35.25% of the global revenue in 2023 due to increased awareness about family planning and rapid technological advancements in contraception. In addition, the approval and launch of new contraceptives contribute to the market growth. For instance, in July 2023, the U.S. FDA approved a nonprescription tablet, Opill (norgestrel). It is the first daily oral contraceptive in the U.S. to use without a prescription.Supportive reimbursement policies by private & government organizations are further estimated to boost market growth. According to a report published by the UN Department of Economic and Social Affairs, around 922 million women of reproductive age (or their partners) were using some form of contraception, and pills were the most common form of contraceptive method used in the U.S.
The menopause segment is expected to grow at the highest CAGR of 9.6% for the forecast period. The growth can be attributed to the increasing population of women reaching menopause and issues and the launch of new products for these conditions. For instance, in December 2023, Astellas Pharma Inc. announced the approval of VEOZA (fezolinetant) 45 mg to treat vasomotor symptoms caused by menopause.
Prolia segment led the market in 2023 and is expected to grow at fastest growth rate over the forecast period. Prolia is a medication used in the field of women's health for the treatment and prevention of osteoporosis in postmenopausal women. The generic name for Prolia is denosumab. Prolia is a monoclonal antibody that works by inhibiting a protein called RANK ligand, which plays a key role in the process of bone resorption. By blocking the RANK ligand, Prolia helps reduce bone loss, increase bone density, and decrease the risk of fractures in postmenopausal women with osteoporosis. It is typically administered as an injection every 6 months by a healthcare professional.
Minastrin 24 Fe segment is expected to grow at the lucrative CAGR over the forecast period. Minastrin 24 Fe is a brand name for a combination birth control pill used in women's health. It contains two hormones: norethindrone acetate (a progestin) and ethinyl estradiol (an estrogen). It is primarily prescribed as an oral contraceptive to prevent pregnancy. Minastrin 24 Fe works by preventing ovulation (the release of an egg from the ovary), thickening the cervical mucus to inhibit sperm movement, and affecting the lining of the uterus to make it less receptive to implantation. As indicated by its name, Minastrin 24 Fe is designed to be taken for 24 consecutive days, followed by a 4-day pill-free period. This results in menstrual-like withdrawal bleeding during the pill-free days.
Based on the age group segment, the market has been further divided into 50 years & above and others. The others segment dominated the market in 2023 and is expected to sustain the position for the forecast period. Women aged below 50 years are more likely to face issues associated with fertility, such as endometriosis, hormonal infertility, and polycystic ovary syndrome. According to the UNICEF, in 2023, there are around 1.16 billion females below 18 years old globally. Hence, the significant population is prone to several women’s health issues, thereby promoting the market.
The 50 years & above age segment is expected to register the fastest growth rate over the forecast period as an increase in life expectancy is boosting the overall menopausal population across the globe. In addition, with a rise in the geriatric population, diseases, such as postmenopausal osteoporosis are also increasing. According to an article published in NCBI, the prevalence of postmenopausal osteoporosis in women aged 60 to 69 is around 10.95% and about 26.45% in women aged 70 & above. Other women’s health issues, such as endometriosis, are more likely to occur in reproductive age groups; however, it also affects a small percentage of postmenopausal women.All these factors are expected to drive the growth of this segment in the years to come.
The North American region dominated the market in 2023 with a market share of 41.44%. This growth was attributed to the favorable reimbursement policies, approval & commercialization of products, supportive government laws, and high awareness about the importance of maintaining good health. For instance, in July 2023, Canada announced funding to promote women's health and rights at the 2023 Women Deliver Conference. The country allocated USD 10 million for the "Advancing Sexual and Reproductive Health and Rights project" under Canada's SheSOARS initiative. Moreover, in May 2023, U.S. Department of Health and Human Services announced over USD 65 million to 35 HRSA-funded health centers to address the maternal mortality crisis.
Furthermore, Asia Pacific is expected to witness the fastest CAGR from 2024 to 2033 due to the factors, such as increasing awareness about women’s health and wellbeing, rising geriatric population, and various government initiatives for increasing health awareness. India is one of the lucrative markets for women’s health owing to high unmet needs, large patient base, increasing awareness among people, and favorable government initiatives undertaken by government bodies.For instance, according to the PRS Legislative Research, for 2023-2024, the Government of India allocated around USD 10.68 billion, an increase of 13% from the previous year.Moreover, the prevalence of anemia among pregnant women and nonpregnant women in India was approximately 50.3% and 53.2%, respectively, in 2018. Such a high prevalence of anemia is boosting the growth of women’s health market in India.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global women’s health market
Application
Drug
Age
Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers